Medlab (ASX:MDC) ran through the highlights of its most recent earnings period as the firm issued its report for the most recent quarterly period.
As quoted in the press release:
The key highlights for the period have been:
- Recruitment in Medlab’s Phase 2 trial at Royal North Shore Hospital is completed and results expected by Christmas.
- Collections of AU$2.401m, an increase of approx. 96 percent over the corresponding period last year.
- R&D Tax Incentive FY 2019 of AU$2.1m was received in October.
- Agreement executed to expand nutraceuticals to USA
- First export order of Medlab’s newest cannabinoid (NanoCBD) of 1,500 units to Hong Kong received and deposit paid.
The current quarter and first quarter next year are expected to be exciting for the company with the release of Phase 2 trial data and preparation for Phase 3 trial in the US and Australia.
We expect to deliver significant news on progress on across our businesses and exciting opportunities for our customers, our staff and our shareholders.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).